KDR and neoplasm: Decorin demonstrates anti-tumor properties through the direct binding to transforming growth factor-β (TGF-β) and suppressing cell growth as well as acting as a negative regulator toward hepatocyte growth factor receptor (c-Met), insulin-like growth factor receptor I (IGF-IR), vascular endothelial growth factor receptor 2 (VEGFR-2) and platelet-derived growth factor receptor (PDGFR) [62,63].